Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Minghong Bi"'
Autor:
Puyuan Xing, Shanbing Wang, Minghong Bi, Yong Liu, Jia Zeng, Xicheng Wang, Ke Xiao, Weidong Li, Jun Guo, Pu Wang, Yueyin Pan, Biyong Ren, Emei Gao, Lei Zhang, Yingchun Wang, Tianyi Gan, Guang Cheng, Yuankai Shi
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102791- (2024)
Summary: Background: This was a multicenter, single-arm dose-ranging phase 2 study aimed to assess the efficacy and safety of LY01610, a liposomal irinotecan, at various doses for patients with relapsed small cell lung cancer (SCLC). Methods: This st
Externí odkaz:
https://doaj.org/article/36ddc04b9f51424597c83e4755d54a25
Autor:
Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu
Publikováno v:
Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)
Abstract Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized con
Externí odkaz:
https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922e
Autor:
Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang, Yan Yu, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Qisen Guo, Quan Liu, Huijuan Wu, Jian Fang, Yi Hu, Xiuwen Wang, Cuicui Han, Kai Li, Baohui Han
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 816-824 (2021)
Objective: This phase 3 study aimed to test equivalence in efficacy and safety for QL1101, a bevacizumab analogue in Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Eligible patients were ran
Externí odkaz:
https://doaj.org/article/89f482a744bd43afbb9a85d6f45c28a5
Publikováno v:
Future Science OA, Vol 8, Iss 5 (2022)
Purpose: Inflammatory indexes, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and lymphocyte-to-monocyte ratio (LMR), have been confirmed as prognostic factors in multiple
Externí odkaz:
https://doaj.org/article/b386e89212ac4038ab58e1193cc6f201
Autor:
Shilong SONG, Minghong BI
Publikováno v:
Chinese Journal of Lung Cancer, Vol 17, Iss 10, Pp 755-759 (2014)
Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects o
Externí odkaz:
https://doaj.org/article/b09ec6219914415db7019ba4669eab82
Autor:
Jingjing LIU, Minghong BI
Publikováno v:
Chinese Journal of Lung Cancer, Vol 16, Iss 11, Pp 615-620 (2013)
Lung cancer is the leading cause of cancer-related death worldwide, molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. RET fusion gene with an identifiable clinical pathological features, is
Externí odkaz:
https://doaj.org/article/35b914c979af48e987b688d7bad27011
Autor:
Wei HAN, Minghong BI
Publikováno v:
Chinese Journal of Lung Cancer, Vol 16, Iss 2, Pp 97-101 (2013)
Lung cancer continues to be the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Molecular targeted therapy is the most promising development part in the treatment of NSCLC. In re
Externí odkaz:
https://doaj.org/article/f4c21f89eb5b4c04a8419b6acef501a1
Autor:
Huiping Li, Yan Huang, Zhendong Chen, Aiping Zeng, Helong Zhang, Yan Yu, Shihong Wei, Qingshan Li, Xiaojia Wang, Xiangcai Wang, Xiuwen Wang, Runxiang Yang, Xiumei Dai, Minghong Bi, Tao Sun, Qingyuan Zhang, Cuicui Han, Yujie Li, Xiaoyan Kang, Yaxin Liu, Li Zhang
Publikováno v:
BioDrugs. 37:259-269
Autor:
Yuankai, Shi, Shiman, Wu, Ke, Wang, Shundong, Cang, Wenxiu, Yao, Yun, Fan, Lin, Wu, Meijuan, Huang, Xingya, Li, Yueyin, Pan, Zhixiong, Yang, Bo, Zhu, Gongyan, Chen, Jianhua, Shi, Meili, Sun, Jian, Fang, Lijun, Wang, Zhaohong, Chen, Chunling, Liu, Jingzhang, Li, Jiwei, Liu, Shenghua, Sun, Yanqiu, Zhao, Yanzhen, Guo, Zili, Meng, Zhefeng, Liu, Zhigang, Han, Hong, Lu, Rui, Ma, Sheng, Hu, Guofang, Zhao, Zheng, Liu, Congying, Xie, Diansheng, Zhong, Hui, Zhao, Huiqing, Yu, Longzhen, Zhang, Minghong, Bi, Shanyong, Yi, Shuliang, Guo, Tienan, Yi, Wen, Li, Yingcheng, Lin, Yongqian, Shu, Zhendong, Chen, Zhongliang, Guo, Michael, Greco, Tingting, Wang, Haijiao, Shen
Publikováno v:
Journal of Thoracic Oncology. 17:1306-1317
Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFR T790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally
Autor:
Chao Gao, Qian Guo, Chunmei Shi, Zhiwei Tao, Hongyan Ying, Guowen Wang, Yuhong Zhou, Baocheng Wang, Minghong Bi, Gang Huang, Yu Jiang, Qiqing Cai, Yuankai Shi
Purpose:Patients with alveolar soft part sarcoma (ASPS) are rare and have few treatment options. We assessed the activity of geptanolimab (GB226), a fully humanized programmed cell death protein 1 antibody, for patients with unresectable, recurrent,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e74417b98b85798962360d6b83da82e
https://doi.org/10.1158/1078-0432.c.6529583
https://doi.org/10.1158/1078-0432.c.6529583